Document text
Principal Investigator: Kara Elizabeth Rudolph
Organization: COLUMBIA UNIVERSITY HEALTH SCIENCES
Fiscal Year: 2024
Award: $584,911
Funding agency: National Institute on Drug Abuse
The opioid epidemic in the US is a public health emergency, exacerbated by the Covid-19 pandemic. Medi- cations for opioid use disorder (MOUD)-injection naltrexone, buprenorphine, and methadone-are the most effective tools for improving outcomes and preventing overdose among persons with OUD, but engagement in MOUD, especially long-term engagement typically required for a successful outcome, is unacceptably low. Long-term engagement rates tend to be even lower in real-world settings-what NIDA has termed the research-to-practice gap. This discrepancy between trial and real-world MOUD effectiveness could be par- tially attributable to differences between clinical trial versus real-world population characteristics (e.g., in terms of psychiatric and substance use comorbidities, previous treatment experience, immigration status, etc.) if treatment effects are modified (increased/decreased) by some of these characteristics that also relate to trial participation. Moreover, without knowing the relative effectiveness of MOUDs for certain real-world target pop- ulations, clinicians, researchers, and policymakers may be tasked with decision-making with biased evidence. Thus, there is a critical need to improve the generalizability of MOUD trials. Failing to meet this need would further ossify the research-to-practice gap, resulting in suboptimal treatment of OUD overall and within key subgroups. We propose to develop design and analytic approaches, what we call a generalizability through- line, to bridge MOUD trial evidence to real-world populations. The objectives of this project are: In Aim 1), to identify and characterize clinically meaningful, interpretable subgroups of persons seeking OUD treatment in US usual-care settings who are not represented or under-represented in MOUD trials based on multiple char- acteristics simultaneously. This will move us beyond existing approaches for assessing representation that have generally been limited to considering one individual-level characteristic at a time (e.g., race/ethnicity). We will apply the approach developed in the first part of Aim 1 to trial data (3 MOUD trials from NIDA CTN) and population data (California and New Jersey Medicaid claims) to characterize under-represented subgroups. In Aim 2), to generalize MOUD effectiveness to state-specific adult Medicaid populations, thereby estimating a realistic treatment goal if treatment retention supports, incentives, and dosing practices were improved to align with those in trials. Existing approaches for predicting generalized effects rely on extrapolation for non- and under-represented subgroups, which can result in biased and/or uninformative estimates. The approach developed in the first part of Aim 2 will make several improvements to limit extrapolation and increase effi- ciency. In Aim 3), to implement the methods developed for Aims 1 and 2 in user-friendly software to facilitate the easy adoption by applied trialists, researchers, and clinicians. The proposed research is expected to make a significant contribution to improving representation among trial participants and to understanding how and to whom trial findings generalize.
Terms: <21+ years old><Acceleration><Accountability><Adanon><Address><Adoption><Adult><Adult Human><Althose><Automobile collision><Automobile crash><Buprenorphine><COVID crisis><COVID epidemic><COVID pandemic><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 years><California><Car collision><Car crash><Cessation of life><Characteristics><Clinical><Clinical Trials><Clinical Trials Network><Computer Software Tools><Data><Death><Decision Making><Dimensions><Dolophine><Dose><Drugs><Effectiveness><Ensure><Ethnic Origin><Ethnicity><Foundations><Future><Goals><Immigration><Incentives><Individual><Injections><Investigators><Left><Medicaid><Medication><Methadone><Methadose><Methods><Morbidity><Morbidity - disease rate><Motor vehicle collision><Motor vehicle crash><NIDA><Nalorex><Naltrexone><National Institute of Drug Abuse><National Institute on Drug Abuse><Nemexin><New Jersey><Outcome><Output><Overdose><Overdose reduction><Participant><Patients><Persons><Pharmaceutical Preparations><Phase><Physiologic Ossification><Physiological Ossification><Policies><Policy Maker><Population><Population Characteristics><Process><Provider><Race><Races><ReVia><Recovery><Research><Research Personnel><Researchers><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 pandemic><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 pandemic><Software Tools><Subgroup><Target Populations><Time><Treatment Effectiveness><Underrepresented Groups><Underrepresented Populations><Vehicle crash><Vehicular collision><Vehicular crash><Visualization><Vivitrol><Work><adulthood><care as usual><care seeking><clinical trial participant><co-morbid><co-morbidity><comorbidity><comparative treatment><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><data harmonization><design><designing><drug/agent><evidence base><experience><harmonized data><improved><improved outcome><medication for opioid use disorder><mortality><normal ossification><opiate crisis><opiate use disorder><opioid crisis><opioid epidemic><opioid use disorder><ossification><patient population><prevent><preventing><public health emergency><racial><racial background><racial origin><reduce overdose><reduction in overdose><relative effectiveness><research into practice><research to practice><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><socio-demographics><sociodemographics><software toolkit><substance use><substance using><tool><traffic collision><traffic crash><treatment as usual><treatment effect><trial design><under representation of groups><under represented groups><under represented people><under represented populations><underrepresentation of groups><underrepresented people><user friendly computer software><user friendly software><usual care>